TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
about
Of mice and women: a comparative tissue biology perspective of breast stem cells and differentiationNext-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situGenomic profiling of breast cancersBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Molecular Classification of Triple-Negative Breast CancerA Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsExpression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.DupChecker: a bioconductor package for checking high-throughput genomic data redundancy in meta-analysisRNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data MiningSingle-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerCharacterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian WomenPatient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancerMolecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusPIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.Mouse mammary stem cells express prognostic markers for triple-negative breast cancerGene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesRefinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer.Patient-derived breast tumor xenografts facilitating personalized cancer therapy.A single-nucleotide polymorphism in the 3'-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer.Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkersDifferential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.RANKL/RANK control Brca1 mutation-driven mammary tumors.The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
P2860
Q26796835-165233C3-7955-4BF8-9315-C33E23E858BFQ26864448-F78FE42E-8A45-4611-BF33-FB1E99A6A3C6Q27013013-CFF2AB76-ABB3-4A98-A330-156CB4D717CEQ27311085-2EF78963-9534-4B4B-B276-2DF7DF1DD88EQ28076661-55FF0B13-ED65-4225-BD4C-707636B15DA3Q30253017-9C15587F-C4C9-4C6C-9978-8DEE535F1712Q30491493-234FCA81-4F17-4654-B1CB-FC2068752C8DQ30856115-46605141-DA59-441A-BDB4-909B77341026Q31138624-EDD519B7-E196-4AA3-8F0B-E463497B71CFQ33654352-E65E43A8-307E-43C3-AFE7-99A2D4814371Q33680293-61FF3056-6706-4082-8DF6-D04F6A4BDC31Q33697429-459CE53A-D2D0-43C9-B497-F183988E3397Q33739184-9BCEF1D8-9254-4271-865C-B1696AA0F512Q33739807-2C67E940-D2CC-47C0-B6B8-AA644CECA137Q33767473-DD1D9AE3-BE36-44C5-950A-31986F08E431Q33874621-CBAC399A-086B-44EE-B177-3B237C529C62Q33896844-F33C6EFB-2BAA-4168-8F3A-CD5E2248246AQ34038170-94C57498-18B5-474F-BE3F-EC8B37B03987Q34296476-9E49E032-8A1B-42C3-8DAB-2B07AF5848C3Q34773994-87B38FC0-29D0-44DB-AF4A-96319B6EC305Q35185688-80B7DA1E-2C98-44AF-BB75-C9128A91AAE2Q35238287-D4F24D5F-0D6F-4B1B-9AF9-155968695A95Q35314135-0ED87B8E-B2FF-42D2-AD34-8AA7F5BEB026Q35671951-1CABD9A9-9EF6-4ABC-8C13-3644A6DF944DQ35941029-1E7C231C-3B9B-49B4-8DE7-FECA60164950Q35958861-08221A4E-1DE1-4A31-8491-F857D037D5F2Q36054418-61013542-4528-4385-B1F0-29705286C62CQ36109265-8EADAADE-A52E-4BB8-8787-AD56613212E2Q36334470-93BE84FC-9896-4E9E-B9DE-74C1BA1B5052Q36383626-D6DDDD95-993C-40DA-8A50-D36AAC887394Q36686920-BFFEA0F9-711E-4DE9-BBCA-0D0A6A80A864Q36758895-661A7D7E-DAB6-4E12-B46E-934BCF7CDEE7Q36903447-D8D5A63C-FCC5-47BF-B336-61258DFF7BC7Q37109912-88E593E0-5858-456F-8638-D1C2BC3830B3Q37120868-5C5B24C0-D871-48F4-8ACF-4F6A3D827A78Q37163880-9B45BF25-F0BE-4B86-BD7B-AEA5E3823034Q37190437-B630D01C-A814-4272-82F1-EE6CFD1B4585Q37269261-9EE27F33-CB7D-4000-9C35-B0478F50B616Q37457304-C821F998-3CA6-4E23-BBF8-E90E12320572Q37510518-D7C43311-6789-42D2-A874-134ABEE2F1F8
P2860
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
@ast
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
@en
type
label
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
@ast
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
@en
prefLabel
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
@ast
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
@en
P2093
P2860
P356
P1433
P1476
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
@en
P2093
Joshua A Bauer
William H Gray
P2860
P304
P356
10.4137/CIN.S9983
P577
2012-07-24T00:00:00Z